Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia

References

• American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
   PubMed Web of Science ®Google Scholar
• Muscedere JG, Day A, Heyland DK. Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia. Clin Infect Dis. 2010;51(Suppl 1):S120–S125.
   Google Scholar
• Lagamayo EN. Antimicrobial resistance in major pathogens of hospital-acquired pneumonia in Asian countries. Am J Infect Control. 2008;36(Suppl 4):S101–S108.
   PubMed Web of Science ®Google Scholar
• Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med. 1998;157:531–539.
   PubMed Web of Science ®Google Scholar
• Dupont H, Mentec H, Sollet JP, et al. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator associated pneumonia. Intensive Care Med. 2001;27:355–362.
   PubMed Web of Science ®Google Scholar
• Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis. 2000;31(Suppl 4):S131–S138.
   PubMed Web of Science ®Google Scholar
• Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator associated pneumonia. Chest. 2002;122:262–268.
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012. Intensive Care Med. 2013;39:165–228.
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–1596.
   PubMed Web of Science ®Google Scholar
• Rello J, Sa-Borges M, Correa H, et al. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med. 1999;160:608–613.
   PubMed Web of Science ®Google Scholar
• Niederman MS. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin Infect Dis. 2006;42(Suppl 2):72–81.
   Web of Science ®Google Scholar
• Hernández G, Rico P, Díaz E, et al. Nosocomial lung infections in adult intensive care units. Microbes Infect. 2004;6:1004–1014.
   PubMed Web of Science ®Google Scholar
• Torres A, Ewig S, Lode H, et al. for The European HAP working group. Defining, treating and preventing hospital acquired pneumonia: European perspective. Intensive Care Med. 2009;35:9–29.
   PubMed Web of Science ®Google Scholar
• Dalhoff K, Ewig S, Abele-Horn M, et al. on behalf of the Guideline Development Group. Adult patients with nosocomial pneumonia: epidemiology, diagnosis, and treatment. Dtsch Arztebl Int. 2013;110:634–640.
   PubMed Web of Science ®Google Scholar
• Bodmann KF. Current guidelines for the treatment of severe pneumonia and sepsis. Chemotherapy. 2005;51:227–233.
   PubMed Web of Science ®Google Scholar
• Rotstein C, Evans G, Born A, et al. Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol. 2008;19:19–53.
   PubMed Web of Science ®Google Scholar
• Bartlett JG, Barie PS, Niederman MS, et al. Workshop on clinical trials of antibacterial agents for hospital-acquired pneumonia and ventilator-asociated pneumonia. Clin Infect Dis. 2010;51(Suppl 1):S1–S3.
   PubMed Web of Science ®Google Scholar
• Kollef MH. Review of recent clinical trials of hospital-acquired pneumonia and ventilator-associated pneumonia: a perspective from Academia. Clin Infect Dis. 2010;51(Suppl 1):S29–S35.
   PubMed Web of Science ®Google Scholar
• Sorbello A, Komo S, Valappil T, et al. Registration trials of antibacterial drugs for the treatment of nosocomial pneumonia. Clin Infect Dis. 2010;51(Suppl 1):S26–S41.
   Google Scholar
• Park DR. The microbiology of ventilator-associated pneumonia. Respir Care. 2005 Jun;50:742–763.
   PubMedGoogle Scholar
• Barbier F, Andremont A, Wolff M, et al. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med. 2013;19:216–228.
   PubMed Web of Science ®Google Scholar
• Antimicrobial resistance: global report on surveillance 2014. World Health Organization; 2014 [cited 2015 Oct 3]. Available from: http://www.who.int/drugresistance/documents/surveillancereport/en/.
   Google Scholar
• Zahar JR, Lortholary O, Martin C, et al. Addressing the challenge of extended-spectrum b-lactamases. Curr Opin Investig Drugs. 2009;10:172–180.
   PubMedGoogle Scholar
• Cantón R, Akóva M, Carmeli Y, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect. 2012;18:413–431.
   PubMed Web of Science ®Google Scholar
• Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17:791–798.
   Web of Science ®Google Scholar
• Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13:785–796.
   PubMed Web of Science ®Google Scholar
• Nordmann P, Cornaglia G. Carbapenemase-producing Enterobacteriaceae: a call for action!. Clin Microbiol Infect. 2012;18:411–412.
   PubMed Web of Science ®Google Scholar
• Cornaglia G, Giamarellou H, Rossolini GM. Metallo-b-lactamases; a last frontier for b-lactams? Lancet Infect Dis. 2011;11:381–393.
   PubMed Web of Science ®Google Scholar
• Lee C-S, Doi Y. Therapy of infections due to carbapenem-resistant gram-negative pathogens. Infect Chemother. 2014;46:149–164.
   PubMedGoogle Scholar
• Spellberg B, Blaser M, Guidos RJ, et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. 2011;52(Suppl 5):S397–S428.
   PubMedGoogle Scholar
• Restrepo MI, Peterson J, Fernandez JF, et al. Comparison of the bacterial etiology of early-onset and late-onset ventilator-associated pneumonia in subjects enrolled in 2 large clinical studies. Respir Care. 2013;58:1220–1225.
   PubMed Web of Science ®Google Scholar
• Torres A, Ferrer M, Badia JR. Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia. Clin Infect Dis. 2010;51(Suppl 1):S48–53.
   PubMed Web of Science ®Google Scholar
• Nair GB, Niederman MS. Ventilator-associated pneumonia: present understanding and ongoing debates. Intensive Care Med. 2015;41:34–48.
   PubMed Web of Science ®Google Scholar
• Wilke M, Grube R. Update on management options in the treatment of nosocomial and ventilator assisted pneumonia: review of actual guidelines and economic aspects of therapy. Infect Drug Resist. 2013;7:1–7.
   PubMedGoogle Scholar
• Ferrer M, Menendez R, Amaro R, et al. The impact of guidelines on the outcomes of community-acquired and ventilator-associated pneumonia. Clin Chest Med. 2011;32:491–505.
   PubMed Web of Science ®Google Scholar
• Piskin N, Aydemir H, Oztoprak N, et al. Inadequate treatment of ventilator-associated and hospital acquired pneumonia: risk factors and impact on outcomes. BMC Infect Dis. 2012;12:268.
   PubMed Web of Science ®Google Scholar
• Wilke MH, Grube RF, Bodmann KF. Guideline-adherent initial intravenous antibiotic therapy for hospital-acquired/ventilator-associated pneumonia is clinically superior, saves lives and is cheaper than non guideline adherent therapy. Eur J Med Res. 2011;16:315–323.
   PubMed Web of Science ®Google Scholar
• Soo Hoo GW, Wen YE, Nguyen TV, et al. Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. Chest. 2005;128:2778–2787.
   PubMed Web of Science ®Google Scholar
• Kett DH, Cano E, Quartin AA, et al. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicenter cohort study. Lancet Infect Dis. 2011;11:181–189.
   PubMed Web of Science ®Google Scholar
• Housman ST, Pope JS, Russomanno J, et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200 milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother. 2012;56:2627–2634.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawson CD, Zelenitsky S, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther. 2012;10:459–473.
   PubMed Web of Science ®Google Scholar
• Cass RT, Brooks CD, Havrilla NA, et al. Pharmacokinetics and safety of single and multiple dose of ACHN-490 injection administered intravenously in healthy subjects. Antimicrob Agents Chemother. 2011;55:5874–5880.
   PubMed Web of Science ®Google Scholar
• Jones RN, Moet GJ, Sader HS, et al. TR-700 in vitro activity against and resistance mutation frequencies among gram-positive pathogens. J Antimicrob Chemother. 2009;63:716–720.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, et al. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J Antimicrob Chemother. 2009;63:713–715.
   PubMed Web of Science ®Google Scholar
• Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. Jama. 2013;309:559–569.
   PubMed Web of Science ®Google Scholar
• Moran GJ, Fang E, Corey GR, et al. Once-daily tedizolid for 6 days versus twice-daily linezolid for 10 days in acute bacterial skin and skin structure infections: results from a randomized controlled trial using an intravenous-to-oral switch strategy (ESTABLISH-2 study). Lancet Infect. Dis. 2014;14:696–705.
   PubMed Web of Science ®Google Scholar
• Bien P, Prokocimer P, Munoz KA, et al. Absolute bioavailability of TR-701 FA and pharmacokinetics after single and multiple dose intravenous administration in healthy adult subjects. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010 Sept 12–15; Boston, MA. Abstract A1-013.
   Google Scholar
• Moya B, Zamorano L, Juan C, et al. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54:3933–3937.
   PubMed Web of Science ®Google Scholar
• Sader HS, Rhomberg PR, Farrell DJ, et al. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother. 2011;55:2390–2394.
   PubMed Web of Science ®Google Scholar
• Chandorkar G, Huntington JA, Gotfried MH, et al. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J Antimicrob Chemother. 2012;67:2463–2469.
   PubMed Web of Science ®Google Scholar
• Coleman K. Diazabicyclooctanes (DBOs): a potent new class of non-beta-lactam beta-lactamase inhibitors. Curr Opin Microbiol. 2011;14:550–555.
   PubMed Web of Science ®Google Scholar
• Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20:440–458.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/beta-lactamase inhibitor combination. Drugs. 2013;73:159–177.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 with imipenem vs. beta-lactamase producers. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2012 Sept 9–12; San Francisco, CA. Abstract E-192.
   Google Scholar
• Endimiani A, Hujer KM, Hujer AM, et al. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55:82–85.
   PubMed Web of Science ®Google Scholar
• Crandon JL, Schuck VJ, Banevicius MA, et al. Comparative in vitro and in vivo efficacy of human simulated exposures of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56:6137–6146.
   PubMed Web of Science ®Google Scholar
• Vazquez JA, González Patzán LD, Stricklin D, et al. Efficacy and safety of ceftazidime-avibactam versus imipenemcilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator blinded, randomized study. Curr Med Res Opin. 2012;28:1921–1931.
   PubMed Web of Science ®Google Scholar
• Lucasti C, Popescu I, Ramesh MK, et al. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intraabdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother. 2013;68:1183–1192.
   PubMed Web of Science ®Google Scholar
• Blizzard TA, Chen H, Kim S, et al. Discovery of MK-7655, a beta-lactamase inhibitor for combination with PrimaxinR. Bioorg Med Chem Lett. 2014;24:780–785.
   PubMed Web of Science ®Google Scholar
• Hirsch E, Ledesma KR, Chang K-T, et al. In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2012;56:3753–3757.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Warner M, Mushtaq. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 2013;68:2286–2290.
   PubMed Web of Science ®Google Scholar
• Rizk ML, Jumes P, Lassetter K, et al. Pharmacokinetics of MK-7655, a novel beta-lactamase inhibitor in combination with imipenem/cislatatin in subjects with impaired renal function. 52nd Interscience Conference Antimicrobial Agents Chemotherapy; 2012 Sept 9–12; San Francisco, CA. Abstract A-010.
   Google Scholar
• Jumes P, Rizk ML, Gutierrez M, et al. A phase I study evaluating the single-dose safety, tolerability, and pharmacokinetics of an intravenous beta-lactamase inhibitor in healthy elderly male, elderly female, and young female volunteers. 52nd Interscience Conference Antimicrobial Agents Chemotherapy; 2012 Sept 9–12; San Francisco, CA. Abstract A-009.
   Google Scholar
• Mombelli G, Coppens L, Thys JP, et al. Anti-Pseudomonas activity in bronchial secretions of patients receiving amikacin or tobramycin as a continuous infusion. Antimicrob Agents Chemother. 1981;19:72–75.
   PubMed Web of Science ®Google Scholar
• Ferrari F, Lu Q, Girardi C, et al. Experimental ICU Study Group. Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa. Intensive Care Med. 2009;35:1792–1800.
   PubMed Web of Science ®Google Scholar
• Lu Q, Girardi C, Zhang M, et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med. 2010;36:1147–1155.
   PubMed Web of Science ®Google Scholar
• Luyt C-E, Clavel M, Guntupalli K, et al. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in Intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care. 2009;13:R200.
   PubMed Web of Science ®Google Scholar
• Niederman MS, Chastre J, Corkery K, et al. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with gram-negative pneumonia. Intensive Care Med. 2012;38:263–271.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resitant Enterobacteriaceae isolates. J Antimicrob Chemother. 2011;66:48–53.
   PubMed Web of Science ®Google Scholar
• Endiminani A, Hujer KM, Hujer AM, et al. ACHN-490, a neoglycoside with potent in vitro activity against multidrugresistant Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2010;53:4504–4507.
   Web of Science ®Google Scholar
• Armstrong ES, Miller GH. Combating evolution with intelligent design: the neoglycoside ACHN-490. Curr Opin Microbiol. 2010;13:565–573.
   PubMed Web of Science ®Google Scholar
• Landman D, Kelly P, Bäcker M, et al. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J Antimicrob Chemother. 2011;66:332–334.
   PubMed Web of Science ®Google Scholar
• Aggen JB, Armstrong ES, Goldblum AA, et at. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother. 2010;54:4636–4642.
   PubMed Web of Science ®Google Scholar
• Reyes N, Aggen JB, Kostrub CF. In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infections models. Antimicrob Agents Chemother. 2011;55:1728–1733.
   PubMed Web of Science ®Google Scholar
• Connors KP, Housman ST, Pope JS, et al. A phase I, open-label, safety and pharmacokinetic study to assess brochopulmonary disposition of intravenous eravacycline in healthy men and woman. Antimicrob Agents Chemother. 2014;58:2113–2118.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Alley MRK, Sader HS, et al. Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli. Antimicrob. Agents Chemother. 2013;57:2849–2857.
   PubMed Web of Science ®Google Scholar
• Wilbraham S, DeMarco S, Ograbek A, et al. Phase 1 study with the novel Pseudomonas aeruginosa antibiotic POL7080 in healthy volunteers. 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2011 May 7–10; Milan. Abstract P1513.
   Google Scholar
• Sutcliffe JA, O’Brien W, Fyfe C, et al. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob. Agents Chemother. 2013;57:5548–5558.
   PubMed Web of Science ®Google Scholar
• Solomkin J, Cesnauska G, Ramesh M, et al. Efficacy and safety of TP-434 (eravacycline) versus ertapenem in complicated intra-abdominal infection (cIAI). 52nd Interscience Conference Antimicrobial Agents Chemotherapy; 2012 Sept 9–12; San Francisco, CA. Abstract L1-1647a.
   Google Scholar
• Matsumoto T. Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant gram-negative pathogens. Clin Pharmacol. 2014;6:139–148.
   PubMedGoogle Scholar
• Sader HS, Rhomberg PR, Farrell DJ, et al. Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia. Antimicrob Agents Chemother. 2015;59:3263–3270.
   PubMed Web of Science ®Google Scholar
• Hamada Y, Suematsu H, Hirai J, et al. Evaluation of six cases of arbekacin inhalation for pneumonia. Jpn J Antibiot. 2014;67:233–239.
   Web of Science ®Google Scholar
• Kaku N, Yanagihara K, Takeda K, et al. In vivo efficacy of ME1100, an arbekacin inhalation solution, in a murine model of ventilator-associated pneumonia caused by Pseudomonas aeruginosa. 54th Interscience Conference Antimicrobial Agents Chemotherapy; 2014 Sept 5–9; Washington, DC. Abstract E-211.
   Google Scholar
• Hernandez V, Akama T, Alley M, et al. Discovery and mechanism of action of AN3365: a novel boron-containing antibacterial agent in clinical development for gram-negative infections. 51th Interscience Conference Antimicrobial Agents Chemotherapy; 2011 Sept 17–20; Chicago, IL. Abstract F1-1637.
   Google Scholar
• Mendez RE, Biedenbach DJ, Alley MRK, et al. Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against Enterobacteriaceae. 51th Interscience Conference Antimicrobial Agents Chemotherapy; 2011 Sept 17–20; Chicago, IL. Abstract F1-1638.
   Google Scholar
• Andes DR, Okusanya OO, Bulik CC, et al. Evaluation of the pharmacokinetics pharmacodynamics of GSK2251052 against gram-negative bacilli using data from a neutropenic murine-pneumonia infection model. 52nd Interscience Conference Antimicrobial Agents Chemotherapy; 2012 Sept 9–12; San Francisco, CA. Abstract A-1271.
   Google Scholar
• Hoover J, Mininger C, Rittenhouse S GSK2251052, a novel LeuRS inhibitor, is effective against multi-drug resistant Pseudomonas aeruginosa in a mouse pneumonia model. 52nd Interscience Conference Antimicrobial Agents Chemotherapy; 2012 Sept 9–12; San Francisco, CA. Abstract B-1308.
   Google Scholar
• Craven DE. Epidemiology of ventilator-associated pneumonia. Chest. 2000;117(Suppl 4):186S–7.
   Google Scholar
• Tenero D, Bowers G, Rodvold KA, et al. Intrapulmonary pharmacokinetics of GSK2251052 in healthy volunteers. Antimicrob Agents Chemother. 2013;57:3334–3339.
   PubMed Web of Science ®Google Scholar
• Page MG, Dantier C, Desarbre E. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistent gram-negative bacilli. Antimicrob Agents Chemother. 2010;54:2291–2302.
   PubMed Web of Science ®Google Scholar
• Morissey I, Siegmund C, Genet E, et al. Activity of BAL30072 alone and in combination with carbapenems against gram-negative bacteria. 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2014 May 10–13; Barcelona. Abstract P0296.
   Google Scholar
• Srinivas N, Jetter P, Ueberbacher BJ, et al. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science. 2010;327:1010–1013.
   PubMed Web of Science ®Google Scholar
• VingsboLundberg C, Bernardini F, Dembowsky K, et al. POL7080 is highly efficacious in the murine pneumonia model. 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2014 May 10–13; Barcelona. Abstract P0302.
   Google Scholar
• Sader H, Biedenbach DJ, Jones RN,et al. In vitro evaluation of antimicrobial spectrum and determination of optimal MIC test conditions for the novel protein epitope mimetics antibiotic POL7080. 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2012 Mar 31–Apr 3; London. Abstract P1456.
   Google Scholar
• Kuhlmann O, Brealey C, Simon S, et al. Metabolism and excretion of the new LptD peptide antibiotic RG7929. 55th Interscience Conference Antimicrobial Agents Chemotherapy; 2015 Sept 18–21; San Diego, CA. Abstract A-973.
   Google Scholar
• Muller AE, Dale G, Mouton JW New therapeutic alternatives. The impact of creatinine clearance on the dosing of POL7080, a new macrocyclic antibiotic. 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2014 May 10–13; Barcelona. Abstract P0303.
   Google Scholar
• Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol. 2007;3:541–548.
   PubMed Web of Science ®Google Scholar
• Lu Q, Rouby J-J, Laterre P-F, et al. Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with hospital-acquired Pseudomonas aeruginosa O11 pneumonia. J Antimicrob Chemother. 2011;66:1110–1116.
   PubMed Web of Science ®Google Scholar
• François B, Luyt C-E, Dugard A, et al. Safety and pharmacokinetics of an anti PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial. Crit Care Med. 2012;40:2320–2326.
   PubMed Web of Science ®Google Scholar
• Gafner VC, Lazar H, Mus E, et al. Pseudomonas aeruginosa serotypes in hospital-acquired pneumonia: prevalence, patient characteristics and clinical outcome. 50th Interscience Conference Antimicrobial Agents Chemotherapy; 2010 Sept 12–15; Boston, MA. Abstract K-2180.
   Google Scholar
• Horn MP, Zuercher AW, Imboden MA, et al. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrob Agents Chemother. 2010;54:2338–2344.
   PubMed Web of Science ®Google Scholar
• Lazar H, Horn MP, Zuercher AW, et al. Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. Antimicrob Agents Chemother. 2009;53:3442–3446.
   PubMed Web of Science ®Google Scholar
• Que Y-A, Lazar H, Wolff M, et al. Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis. 2014;33:1861–1867.
   PubMed Web of Science ®Google Scholar
• Coburn B, Sekirov I, Finlay BB. Type III secretion systems and disease. Clin Microbiol Rev. 2007;20:535–549.
   PubMed Web of Science ®Google Scholar
• Hueck CJ. Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol Mol Biol Rev. 1998;62:379–433.
   PubMed Web of Science ®Google Scholar
• Roy-Burman A, Savel RH, Racine S, et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis. 2001;183:1767–1774.
   PubMed Web of Science ®Google Scholar
• Finck-Barbançon V, Goranson J, Zhu L, et al. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol Microbiol. 1997;25:547–557.
   PubMed Web of Science ®Google Scholar
• Yahr TL, Vallis AJ, Hancock MK, et al. ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system. Proc Natl Acad Sci USA. 1998;95:13899–13904.
   PubMed Web of Science ®Google Scholar
• Schulert GS, Feltman H, Rabin SD, et al. Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J Infect Dis. 2003;188:1695–1706.
   PubMed Web of Science ®Google Scholar
• Dacheux D, Toussaint B, Richard M, et al. Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils. Infect Immun. 2000;68:2916–2924.
   PubMed Web of Science ®Google Scholar
• Lynch SV, Flanagan JL, Sawa T, et al. Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV – implications for anti-PcrV immunotherapy. Microb Pathog. 2010;48:197–204.
   PubMed Web of Science ®Google Scholar
• Faure K, Fujimoto J, Shimabukuro DW, et al. Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model. J Immune Based Ther Vaccines. 2003;1:1–9.
   PubMedGoogle Scholar
• Frank DW, Vallis A, Wiener-Kronish JP, et al. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis. 2002;186:64–73.
   PubMed Web of Science ®Google Scholar
• Neely AN, Holder IA, Wiener-Kronish JP, et al. Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge. Burns. 2005;31:153–158.
   PubMed Web of Science ®Google Scholar
• Sawa T, Yahr TL, Ohara M, et al. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med. 1999;5:392–398.
   PubMed Web of Science ®Google Scholar
• Baer M, Sawa T, Flynn P, et al. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun. 2009;77:1083–1090.
   PubMed Web of Science ®Google Scholar
• Shime N, Sawa T, Fujimoto J, et al. Therapeutic administration of anti-PcrV F(ab’)(2) in sepsis associated with Pseudomonas aeruginosa. J Immunol. 2001;167:5880–5886.
   PubMed Web of Science ®Google Scholar
• Hua L, Hilliard JJ, Shi Y, et al. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother. 2014;58:1108–1117.
   PubMed Web of Science ®Google Scholar
• Hua L, Cohen TS, Shi Y, et al. MEDI4893 promotes survival and extends the antibiotic treatment window in a Staphylococcus aureus immunocompromised pneumonia model. Antimicrob Agents Chemother. 2015;59:4526–4532.
   PubMed Web of Science ®Google Scholar